News
New hope for cancer drugs thanks to European Lead Factory partnership
The European Lead Factory (ELF), a pan-European drug discovery project which Lygature proudly coordinates, has helped identify two drug candidates for cancer treatment that have now progressed to phase 1 clinical trial testing.
Through screening of the high-quality ELF compound library, two drug companies, the Israeli SME Metabomed and the German pharmaceutical company Merck KGaA, have discovered compounds that show promise in inhibiting target pathways involved in the development of tumours. Both compounds have now advanced to phase 1 human clinical trials.
The Innovative Health Initiative outlines the details of this exciting development in the latest issue of its Newsletter.
Commenting on the news, Dr Jon de Vlieger, Coordinator of the European Lead Factory and Director of Business Development at Lygature said: "These are two excellent case studies of the impact of our European Lead Factory partnership. It takes time to develop a new drug, but with the right partners, the right mindset, and perseverance, we can truly make a difference.”
--
This news item was originally published on the ELF website. Lygature supports the ELF with overall program management and utilizes its management capabilities to ensure that the project delivers optimal results. For more information on our role, follow this link.